US$ 23.62
glp-1 usage Antagonists Increase Plan Drug Spend - What's Next The Evolution of GLP-1 Users
Description
While positive for consumers, it places significant financial pressure on an already brittle healthcare and Medicare ecosystem
Medicare beneficiaries will pay no more than $50 per monthfor approved treatments like Zepbound and Ozempic

its a win for public health
With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to both help and harm people with eating disorders.
